Exposure-Overall Survival Analysis for Quizartinib in Newly Diagnosed Patients with FMS- Like Tyrosine Kinase 3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukemia

Oncology

Pharmacometrics

Program strategies and efficiencies

Smania G, Glatard A, Vaddady P, Nakayama S, Inoue H, Mezzalana E, Simonsson USH, Abutarif M, Zheng M